Sign in
CompletedNo phase

Metabolomics of Obstructive Sleep Apnea

Key facts

Who runs it
University of Pennsylvania
Where
Philadelphia, United StatesSee the siteAlso in 1 other country, 1 site
Trial code
Status
Completed
People taking part
388 people enrolled
Started
29 Sept 2020
Ended
12 Sept 2025
Type of study
Observational
Record updated
14 May 2026

Who can take part

Age
30 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged 30-75 years old
  • In good general health as evidenced by medical history and diagnosed with Obstructive Sleep Apnea (defined as AHI>5)
  • Ability to use accelerometer, perform Type 2 sleep test at home and agree to use PAP treatment
  • For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation

Who cannot take part

  • Current drug or alcohol abuse
  • Known allergic reactions to components of the plastic (used in PAP mask)
  • Febrile illness within 2 weeks of signing consent
  • Known diagnosis and treatment of diabetes because this will independently alter metabolomic results
  • Presence of active cancer treatment or heart failure (ejection fraction <40%)
  • Previously drawn laboratory Hemoglobin A1C above normal range (indicative of diabetes)
  • Current use of PAP treatment or mandibular advancement device or INSPIRE device
  • Pregnancy or lactation

Where in United States

Also in 1 other country, 1 site

  • University of PennsylvaniaPhiladelphia, United States

About the trial

What the trial wants to find out

This is an R01 funded project that focuses on the utility of metabolomics as a biomarker for OSA. Aims 1 and 3 leverages banked samples previously collected from subjects with and without OSA at the University of Pennsylvania and University of Iceland. Aim 2 is a prospective study that will collect serum samples from OSA subjects at the University of Pennsylvania and the University of Iceland.

The group in the trial

  • Subjects with OSA

    Female and male subjects with Obstructive Sleep Apnea (OSA) (AHI \>5)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
14 May 2026